BioLineRx Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- Nasdaq futures slide as AI warnings rattle markets; Nvidia, other chip stocks retreat
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% amid Saudi pipeline outage after attack
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street's new pair trade: Long software, short chips
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q3 Results
November 22, 2016 2:39 PM ESTRoth Capital affirms BioLineRx (Nasdaq: BLRX) with a Buy rating and $7 price target following Q3 results reported on Tuesday.
The analyst commented, We are encouraged by the multiple collaborations initiated between BLRX and biopharma in both clinical and preclinical staged projects, spanning multiple indications.
We believe that BL-8040 remains the lead value driver for BLRX with 1) partial results for the Phase II study of... More
BioLineRx (BLRX) Tops Q3 EPS by 4c
November 22, 2016 8:07 AM ESTBioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.03), $0.04 better than the analyst estimate of ($0.07).
The Company held $38.9 million in cash, cash equivalents and short-term bank deposits as of September 30, 2016.
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
... More